Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2019 May 10;375:32–45. doi: 10.1016/j.taap.2019.05.009

Figure 7.

Figure 7

Obesity amplifies gadolinium-based contrast agent-induced kidney injury. A. Renal fibrosis from gadolinium-based contrast agents, obesity, and the combination of the two. Upper panels, PAS, 400 ×. Middle panels, fibronectin. Immunofluorescence, 400×. Lower panels, collagen IV. Immunofluorescence, 400×; calibration bar = 0.05 mm. B. Quantitation of fibrotic markers. Immunoblot. C. Plasma lipid profiles and insulin levels. * P < 0.05, ** P < 0.01, *** P < 0.001 from untreated, chow diet; # P < 0.05, ### P < 0.001 from untreated, high-fat diet; † P < 0.05, ††† P < 0.001 from gadolinium-based contrast agent-treated, chow diet group by analysis-of-variance and Tukey honest significant difference post-hoc testing. D. Renal cortex, with arrows indicating lipofuscin-stained cells. Oil red O, 400_, calibration bars = 0.05 mm.